Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,084 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL, Rizzo CA, West RE Jr, Aslanian R, McCormick K, Bryant M, Hsieh Y, Korfmacher W, Mingo GG, Varty L, Williams SM, Shih NY, Egan RW, Hey JA. McLeod RL, et al. Among authors: bryant m. J Pharmacol Exp Ther. 2003 Jun;305(3):1037-44. doi: 10.1124/jpet.103.049254. Epub 2003 Mar 20. J Pharmacol Exp Ther. 2003. PMID: 12649305
Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template.
Aslanian R, Mutahi MW, Shih NY, McCormick KD, Piwinski JJ, Ting PC, Albanese MM, Berlin MY, Zhu X, Wong SC, Rosenblum SB, Jiang Y, West R, She S, Williams SM, Bryant M, Hey JA. Aslanian R, et al. Among authors: bryant m. Bioorg Med Chem Lett. 2002 Mar 25;12(6):937-41. doi: 10.1016/s0960-894x(02)00055-0. Bioorg Med Chem Lett. 2002. PMID: 11958998
Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
Berlin M, Ting PC, Vaccaro WD, Aslanian R, McCormick KD, Lee JF, Albanese MM, Mutahi MW, Piwinski JJ, Shih NY, Duguma L, Solomon DM, Zhou W, Sher R, Favreau L, Bryant M, Korfmacher WA, Nardo C, West RE Jr, Anthes JC, Williams SM, Wu RL, Susan She H, Rivelli MA, Corboz MR, Hey JA. Berlin M, et al. Among authors: bryant m. Bioorg Med Chem Lett. 2006 Feb 15;16(4):989-94. doi: 10.1016/j.bmcl.2005.10.087. Epub 2005 Nov 15. Bioorg Med Chem Lett. 2006. PMID: 16297617
Metabolism-based identification of a potent thrombin receptor antagonist.
Clasby MC, Chackalamannil S, Czarniecki M, Doller D, Eagen K, Greenlee W, Kao G, Lin Y, Tsai H, Xia Y, Ahn HS, Agans-Fantuzzi J, Boykow G, Chintala M, Foster C, Smith-Torhan A, Alton K, Bryant M, Hsieh Y, Lau J, Palamanda J. Clasby MC, et al. Among authors: bryant m. J Med Chem. 2007 Jan 11;50(1):129-38. doi: 10.1021/jm061043e. J Med Chem. 2007. PMID: 17201416
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Li Z, Dell J, Lipari P, Malkowski M, Prioli N, Rossman RR, Korfmacher WA, Nomeir AA, Lin CC, Mallams AK, Doll RJ, Catino JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR. Liu M, et al. Among authors: bryant ms. Cancer Chemother Pharmacol. 1999;43(1):50-8. doi: 10.1007/s002800050862. Cancer Chemother Pharmacol. 1999. PMID: 9923541
Discovery of nor-seco himbacine analogs as thrombin receptor antagonists.
Chelliah MV, Chackalamannil S, Xia Y, Eagen K, Greenlee WJ, Ahn HS, Agans-Fantuzzi J, Boykow G, Hsieh Y, Bryant M, Chan TM, Chintala M. Chelliah MV, et al. Among authors: bryant m. Bioorg Med Chem Lett. 2012 Apr 1;22(7):2544-9. doi: 10.1016/j.bmcl.2012.01.138. Epub 2012 Feb 16. Bioorg Med Chem Lett. 2012. PMID: 22405832
1,084 results